Neratinib-plus-cetuximab in quadruple-WT (KRAS, NRAS, BRAF, PIK3CA) metastatic colorectal cancer resistant to cetuximab or panitumumab: NSABP FC-7, a phase ib study
Samuel A. Jacobs*, James J. Lee, Thomas J. George, James L. Wade, Philip J. Stella, Ding Wang, Ashwin R. Sama, Fanny Piette, Katherine L. Pogue-Geile, Rim S. Kim, Patrick G. Gavin, Corey Lipchik, Huichen Feng, Ying Wang, Melanie Finnigan, Brian F. Kiesel, Jan H. Beumer, Norman Wolmark, Peter C. Lucas, Carmen J. AllegraAshok Srinivasan*
Dive into the research topics of 'Neratinib-plus-cetuximab in quadruple-WT (KRAS, NRAS, BRAF, PIK3CA) metastatic colorectal cancer resistant to cetuximab or panitumumab: NSABP FC-7, a phase ib study'. Together they form a unique fingerprint.